Investigator-Initiated Protocols – 2012- present

MicroRNA Expression in Patient Metastatic Brain Lesions

Principal Investigator

MicroRNA Expression in Patient Primary Brain Tumors

Principal Investigator

A pilot study to compare non-coding RNA in multiple myeloma patients, MGUS patients and healthy individuals using bone marrow and peripheral blood

Principal Investigator

A pilot study to compare the isolation of circulating tumor cells from peripheral blood and by diagnostic leukapheresis in multiple myeloma patients and healthy individuals

Principal Investigator

Specific targeting of bone marrow niche-resident long lived plasma cells by combined therapy with bortezomib and plerixafor

Co-Principal Investigator; Sponsor - Millennium-Takeda, Cambridge, MA

Velcade-based Desensitization Kidney Transplant Protocol Protocol Synopsis

Co-Principal Investigator; Sponsor- Onyx Pharmaceuticals – South San Francisco, CA

A phase I/II clinical trial of Metformin combined with Velcade and Dexamethasone in newly diagnosed Multiple Myeloma

Principal Investigator

A Phase 1 Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors

Co-Investigator

Publications


Alsiwadi, S, Malek, E, Driscoll, JJ (2014). MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics In: The International Journal of Molecular Sciences; Special issue: Brain Metastasis 2014, guest editor: Dario Marchetti, PhD, (in review).

Medhat, MA, Abdel Malek, MAY, Zaki, S, Helmy, S, Driscoll, JJ (2014) Rare extraperitoneal involvement with fatal outcome in a case of bilateral luteinized thecoma of the ovaries with sclerosing peritonitis. Case Reports in Oncology (in review).

Jagannathan, S., Cheong, H., Abplanalp, W., Vallabhapurapu, Su., Vallabhapurapu, Si., Lindsten, T., Driscoll, JJ (2014). Phenformin, independent of AMPK, activates 4E-BP to inhibit autophagy and enhance bortezomib-induced cytotoxicity, (in revision).

Abdel Malek, MAY, Sayed, DM, Ahmad, YA, Driscoll, JJ (2014) Chronic eosinophilic leukemia transformation into acute myeloid leukemia with monocytic differentiation. Case Reports in Internal Medicine 1:4-9.

Haider, S, Ahmad, N, Anaissie, E, Driscoll, JJ (2013) Future directions in the clinical management of amyloid light chain amyloidosis. Leukemia and Lymphoma (Dec. 2013; doi: 0.3109/10428194.2013.876630).

Ahmad, N., Abdel Malek, MA, Anaissie, E., Driscoll, JJ. Targeting the proteasome pathway for the treatment of solid tumors “Resistance to proteasome inhibitors" (Ed. Q. Ping Dou) Cancer Research Springer Science. (in press).

Kim, KJ, Godarova, A., Seedle, K., Kim, MH, Ince, TA, Wells, SI, Driscoll, JJ and Godar, S. (2013) Rb suppresses collective invasion, circulation and metastasis of breast cancer cells in a CD44-Dependent manner. Plos One (Nov. 2013; doi: 10.1371/journal. pone.0080590).

Abdel Malek, MA and Driscoll, JJ (2013) Molecular crosstalk between autophagy and apoptosis networks in cancer. Autophagy (Ed. Hayat) (in press).

Ahmad, N., Haider, S, Anaissie, E., Driscoll, JJ (2013) MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia doi:10.1038/leu.2013.262

Subramani, A., Alsidawi, A., Jagannathan S., Sumita, K., Sasaki, AT, Aronow, B., Warnick, RE, Lawler, S. and Driscoll, JJ (2013) Brain microenvironment-induced reduction in microRNA-768-3p promotes metastatic tumor growth, drug resistance and KRAS expression. Nature-Scientific Reports 3, doi:10.1038/Srep 02392.

Potluri, V., Noothi, S.K., Vallabhapurapu, S.D., Yoon, S-O, Driscoll, JJ, Lawrie, C.H. and Vallabhapurapu, S. (2013). Transcriptional Repression by a novel YY1-RelA complex is essential for the survival and growth in multiple myeloma. PLoS ONE 8(7): e66121. Aug. 2013; doi:10.1371/journal.pone.0066121.

Driscoll, JJ, Khaled, A, Jagannathan, S. and Subramani, A. (2013) The Mammalian Target of Rapamycin as a Therapeutic Strategy in Oncology in Mammalian Target of Rapamycin (mTOR): Structure, Signaling Pathways and Biological Effects.

Driscoll, JJ, Khaled, A, Jagannathan, S. and Subramani, A. (2013) Targeting the PTEN Tumor Suppressor as an Anti-Cancer Therapeutic Strategy. In PTEN: Structure, Mechanisms-of-Action, Role in Cell Signaling and Regulation.

Driscoll, J.J.., De Chowdhury, R. (2013)Molecular Crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications, Cancer Letters 325 147-154.

Driscoll, JJ. , Woodle, E.S., (2012) Targeting the ubiquitin+proteasome system in solid tumors, Sem. in Hem. 49 277-83.

Driscoll, JJ. , Burris, J., Annunziata, C.M., (2012)Targeting the Proteasome with Bortezomib in Multiple Myeloma: Update on therapeutic benefit as an upfront single agent, induction regimen for stem cell transplantation and as maintenance therapy. Amer. J. Ther. 19 133-44.

Driscoll, JJ. , The SUMOylation pathway as a potential therapeutic target in Multiple Myeloma, Multiple Myeloma- an overview (2011) 129-136.

Driscoll, JJ. , Minter, A., Driscoll, D. The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies. Anti-Cancer Agents in Medicinal Therapy, 11(2) (2011) 242-6.

Driscoll, JJ. , DeChowdhury, R., Therapeutically Targeting the SUMOylation, Ubiquitination and Proteasome Pathways as a Novel Anticancer Strategy. Targeted Oncology 5 (2010) 281-289.

Driscoll, JJ. , Burris, J., Annunziata, C.M., Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy, J. Cell Sci. 1 (2010) 101-8.

Driscoll, JJ. , De Chowdhury, R., Burris, J. et al., The Expanding Role of Proteasome-Based Therapy in the Treatment of Hematologic Malignancies. Open J. Hematology, 1 (2010) 1-20.

Driscoll, JJ. , Rixe, O. in Cancer: Principles & Practice of Oncology. Annual Adv. in Onc. vol I, eds: Devita, V.T., Lawrence, T.S. and Rosenberg, S.A. (2010).

Driscoll, JJ. , Pelluru, D., Lefkimmiatis, K., et al., The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood 115 (2010) 2827-34.

Gabathuler, R., Reid, G., Kolaitis, G., Driscoll, JJ. , and Jefferies, W. A.: Comparison of Cell Lines Deficient in Antigen Presentation Reveals a Functional Role for TAP-1 Alone in Antigen Processing. J. Ex. Med. 180 1415-1425.

Driscoll, JJ. , Brown, M., Finley, D. J. and Monaco, J.J.: MHC-Linked LMP Gene Products Specifically Alter the Peptidase Activities of the Proteasome. Nature (London) 365 262- 264.

Brown, M., Driscoll, JJ. ,. and Monaco, J.J.: MHC-Linked LMP and Proteasome Complexes are Not Identical: Implications for Divergent Function among Immunospecific Forms of the Proteasome. J. Immunol. 151 1193-1204.

Arnold, D., Driscoll, JJ. , Androlewicz, M., Hughes, E., Cresswell, P. and Spies, T.: Proteasome Subunits Encoded in the MHC are Not Generally Required for the Processing of Peptides Bound by MHC Class I Molecules. Nature (London) 360 171-174.

Driscoll, JJ. , and Finley, D. J.: A Controlled Breakdown: Antigen Processing and Turnover of Viral Proteins. Cell 68 823-825.

Driscoll, JJ. , Frydman, J. and Goldberg, A.L.: An ATP-Stabilized Inhibitor of the Proteasome is a Component of the 1,500-kDa Ubiquitin-Conjugate-Degrading Complex. Proc. Natl. Acad. Sci. U.S.A. 89 4986-4990.

Brown, M., Driscoll, JJ. , Monaco, J.J.: Structural and Serological Similarity of the MHC-Linked LMP and the Proteasome (Multicatalytic Protease) Complexes. Nature (London) 353 355-357.

Driscoll, JJ. , and Goldberg, A.L.: The Proteasome (Multicatalytic Protease) is a Component of the 1,500-kDa Proteolytic Complex which Degrades Ubiquitin-Conjugated Proteins. J. Biol. Chem. 265 4789-4792.

Matthews, W., Driscoll, JJ. , Tanaka, K., Ichihara, A. and Goldberg, A.L.: Involvement of the Proteasome in Various Degradative Processes in Mammalian Cells. Proc. Natl. Acad. Sci. U.S.A. 86 2597-2601.

Driscoll, JJ. , and Goldberg, A.L.: Skeletal Muscle Proteasome can Degrade Proteins in an ATP-Dependent Process that does Not Require Ubiquitin. Proc. Natl. Acad. Sci. U.S.A. 86 787-791.